Welcome to Roche Foundation Medicine.

This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as a partner of Foundation Medicine.

Please select an option:



Our FDA-approved liquid biopsy comprehensive genomic profiling service offers a minimally-invasive option, alternative or complementary to FoundationOne CDx, for all patients with solid tumours at optimal times beneficial to their treatment journey1–3

What is FoundationOne Liquid CDx?

Genes and biomarkers

FoundationOne Liquid CDx reports >300 genes and is able to detect both novel and known variants, including four classes of genomic alterations (base substitutions, insertions or deletions, copy number alterations and gene rearrangements), biomarkers (MSI, bTMB) and Tumour Fraction, to provide prognostic, diagnostic and predictive insights that inform research or treatment decisions for individual patients across all solid tumours.‡1,2

Assesses all four main classes of genomic alterations* in >300cancer-related genes, including guideline-recommended genomic alterations associated with available targeted therapies in all solid tumours.1,2,4–11

The FDA-approved liquid biopsy service that reports both MSI and bTMB, pan-tumour biomarkers that may help inform eligibility for immunotherapy.1–3,19–27  

High sensitivity and specificity¥ for key genomic alterations, MSI and bTMB across all solid tumours.1,2

Reports Tumour Fraction, the percentage of tumour-derived circulating cell-free DNA, as a measure of the likelihood of detecting genomic alterations in the liquid biopsy sample.1,2

Faster treatment decisions

Quick and convenient single blood draw helps avoid invasive biopsies and enables faster treatment decisions1,28

FoundationOne Liquid CDx requires only two tubes of blood from a single blood draw (2 x 8.5 mL whole blood) and has a turnaround time of less than 2 weeks from receipt of the sample at our laboratory to report, thereby allowing informed treatment decisions to be made faster.1,28

This may help reduce distress that patients may experience from long waiting times for scheduling a biopsy and receiving the results associated with tissue-based testing.12–15

FoundationOne Liquid CDx may also help reduce requirements for healthcare infrastructure and resources compared with tissue-based testing.29


Based on extensively validated comprehensive platform3,17,18

Like FoundationOne CDx, FoundationOne Liquid CDx is based on an analytically and clinically validated, comprehensive platform and bioinformatics workflow.¶1–3,17,18,30

What is the difference between analytical and clinical validation?

Clinical use in solid cancers

FoundationOne Liquid CDx is suited for all solid tumours including NSCLC, breast cancer, ovarian cancer and prostate cancer1,2,4–11,19-25,33-38

FoundationOne Liquid CDx covers guideline-recommended, and other clinically relevant genomic alterations and biomarkers‡ for NSCLC, breast, ovarian and prostate cancer.1,2,4–11,19–25,33–38

FoundationOne Liquid CDx has demonstrated strong clinical utility

Our previous blood-based comprehensive genomic test demonstrated clinical utility for treatment selection at diagnosis in metastatic NSCLC in BFAST (Blood First Assay Screening Trial), a global, prospective cohort study.30,39

BFAST used an earlier version of Foundation Medicine’s current liquid biopsy service, FoundationOne Liquid CDx. The assay used in BFAST for measuring of ALK+ has been incorporated into FoundationOne Liquid CDx. For concordance results between these two tests, please see our full intended use at www.foundationmedicine.com/F1LCDx.


Sequences circulating cell-free DNA (cfDNA)

FoundationOne Liquid CDx sequences circulating cell-free DNA, which can originate from the primary as well as metastatic tumour sites, thereby capturing the disease heterogeneity across the body as the disease evolves.1,2,14,15

In-depth report

A clear, in-depth report provides insights on your patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials1,2,4–11,41  

Approved targeted therapies and immunotherapies for the patient’s genomic alterations and biomarkers are ranked alphabetically within NCCN therapy categories (for additional information on the NCCN categories please refer to the NCCN Compendium® at www.nccn.org).

When using different Foundation Medicine services across the patient journey, consistency of the reports aid comparison of the results.41,42

The FoundationOne Liquid CDx report includes historic patient findings from earlier FoundationOne tests, allowing you to follow your patient’s genomic profile across their disease journey (availability depending local country data protection regulation).41


Order FoundationOne Liquid CDx

Experience how FoundationOne Liquid CDx can support all patients with solid tumours at optimal times beneficial to their treatment journey.

*Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.

309 genes with complete coding exonic coverage, 15 genes with select intronic or non-coding regions only.

FoundationOne Liquid CDx reports MSI-H status

§Validation based on overall >7,500 samples covering >30,000 unique variants across >300 genes and 37 cancer indications.1,2 To learn more about the clinical and analytical validation of FoundationOne Liquid CDx, click here.

¥75 genes are baited with enhanced sensitivity for all variant types (selected based on increased actionability with current or future targeted therapies; for more information of these 75 genes, please refer to our full gene list); other genomic regions are baited with high sensitivity.

Clinical validation based on evidence gathered using an earlier version of Foundation Medicine’s current liquid biopsy service, FoundationOne Liquid CDx. For concordance results between these two tests, please see our full intended use at www.foundationmedicine.com/F1LCDx.

**For additional information on the NCCN categories please refer to the NCCN Compendium® (www.nccn.org).

bTMB, blood Tumour Mutational Burden; cfDNA, circulating cell-free DNA; CGP, comprehensive genomic profiling; ctDNA, cell-free tumour DNA; d, days; FDA, US Food and Drug Administration; MSI, Microsatellite Instability; NCCN, National Comprehensive Cancer Network; NGS, next generation sequencing; NSCLC, non-small cell lung cancer.

  1. Data on file: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: http://www.eifu.online/FMI/190070862 (Accessed August 2020).
  2. Data on file: Clinical and analytical validation data file for FoundationOne Liquid CDx.
  3. FoundationOne Liquid CDx FDA Approval, 2020. Available at: www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2020).
  4. Planchard D et al. Ann Oncol 2019; 30: 863–870.
  5. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 6.2020, June 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed August 2020).
  6. Cardoso F et al. Ann Oncol 2019; 30: 1674.
  7. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 5.2020, July 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed August 2020).
  8. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2.2020, May 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed August 2020).
  9. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer. Version 1.2020, March 2020. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (Accessed August 2020).
  10. Colombo N et al. Ann Oncol 2019; 30: 672–705.
  11. Parker C et al. Ann Oncol 2020; 31: 1119–1134.
  12. Lebel S et al. J Psychosom Res 2003; 55: 437–443.
  13. Hayes Balmadrid MA et al. J Health Psychol 2017; 22: 561–571.
  14. Francis G, Stein S. Int J Mol Sci 2015; 16: 14122–14142.
  15. Siravegna G et al. Ann Oncol 2019; 30: 1580–1590.
  16. Data on file: FoundationOne Liquid CDx Specimen Instructions.
  17. FoundationOne®CDx FDA Approval, 2017. Available at: 
    https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2020).
  18. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed August 2020).
  19. Kok M et al. ESMO Open 2019; 4(Suppl 2): e000511. 
  20. Zhao P et al. J Hematol Oncol 2019; 12: 54.
  21. Abida W et al. JAMA Oncol 2019; 5: 471–478.
  22. Mateo J et al. Eur Urol 2017; 71: 417–425.
  23. Gandara DR et al. Nat Med 2018; 24: 1441–1448.
  24. Socinski M. Ann Oncol 2019; 30(suppl_5): v851–v934.
  25. Khagi Y et al. Clin Cancer Res 2017; 23: 5729–5736.
  26. FDA approves pembrolizumab for adults and children with TMB-H solid tumors, 2020. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (Accessed August 2020).
  27. Marabelle A et al. Ann Oncol. 2019;30(suppl_5):v475-v532.
  28. Data on file: FoundationOne Liquid CDx Specimen Instructions.
  29. Arnaud A. Value Health 2016. 19: PCN57.
  30. Gadgeel SM et al. Ann Oncol 2019; 30: S5; v851–v934; presented at ESMO 2019.
  31. Merker JD et al. J Clin Oncol 2018; 36: 1631–1641.
  32. Scheerens H et al. Clin Transl Sci 2017; 10: 84–92.
  33. Conway AM et al. Br J Cancer 2019; 120: 141–153.
  34. Amatu A et al. ESMO Open 2016; 1:e000023.
  35. Pikor LA et al. Lung Cancer 2013; 82: 179–189.
  36. Tsao AS et al. J Thorac Oncol 2016; 11: 613–638.
  37. Sanchez-Vega F et al. Cell 2018; 173: 321–337.e10.
  38. Kroeger PT Jr. et al. Curr Opin Obstet Gynecol 2017; 29: 26–34.
  39. Roche Media Release, BFAST, 30 September 2019. Available at: https://www.roche.com/media/releases/med-cor-2019-09-30c.htm (Accessed August 2020).
  40. Dearden S et al. Ann Oncol 2013; 24: 2371–2376.
  41. Data on file: FoundationOne Liquid CDx mock report, 2020. 
  42. FoundationOne®CDx Sample Report. Available at: https://www.foundationmedicine.nl/content/dam/rfm/sample-reports/f1cdx/eu_version_-_ema_without_page_1/F1CDx%20EU%20Sample%20Report%20(Lung).pdf (Accessed August 2020).